Automating classification of treatment responses to combined targeted therapy and immunotherapy in HCC
{{output}}
Tyrosine kinase inhibitors (TKIs) combined with immunotherapy regimens are now widely used for treating advanced hepatocellular carcinoma (HCC), but their clinical efficacy is limited to a subset of patients. Considering that the vast majority of advanced HCC ... ...
